Patents by Inventor Katie Ann Keaton

Katie Ann Keaton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11202780
    Abstract: The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2R,5S,13aR)-7,9-dioxo-10-(2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: December 21, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Ernest A. Carra, Irene Chen, Katie Ann Keaton, Scott E. Lazerwith, Vahid Zia
  • Patent number: 10975096
    Abstract: Methods of making compounds of Formula I are disclosed:
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: April 13, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Anna Chiu, John Enquist, Jr., Nolan Griggs, Christopher Hale, Norihiro Ikemoto, Katie Ann Keaton, Matt Kraft, Scott E. Lazerwith, Michel Leeman, Zhihui Peng, Kate Schrier, Jonathan Trinidad, Jochem Van Herpt, Andrew W. Waltman
  • Publication number: 20200390775
    Abstract: The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2R,5S,13aR)-7,9-dioxo-10-(2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.
    Type: Application
    Filed: January 10, 2020
    Publication date: December 17, 2020
    Inventors: Ernest A. Carra, Irene Chen, Katie Ann Keaton, Scott E. Lazerwith, Vahid Zia
  • Publication number: 20200223866
    Abstract: Methods of making compounds of Formula I are disclosed:
    Type: Application
    Filed: November 18, 2019
    Publication date: July 16, 2020
    Inventors: Anna Chiu, John Enquist, JR., Nolan Griggs, Christopher Hale, Norihiro Ikemoto, Katie Ann Keaton, Matt Kraft, Scott E. Lazerwith, Michel Leeman, Zhihui Peng, Kate Schrier, Jonathan Trinidad, Jochem Van Herpt, Andrew W. Waltman
  • Publication number: 20190015420
    Abstract: The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.
    Type: Application
    Filed: June 14, 2018
    Publication date: January 17, 2019
    Inventors: Ernest A. Carra, Irene Chen, Katie Ann Keaton, Scott E. Lazerwith, Vahid Zia
  • Patent number: 10098886
    Abstract: The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: October 16, 2018
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Ernest A. Carra, Irene Chen, Katie Ann Keaton, Scott E. Lazerwith, Vahid Zia
  • Patent number: 10030033
    Abstract: The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: July 24, 2018
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Amy Cagulada, Johann Chan, Lina Chan, Denise A. Colby, Kapil Kumar Karki, Darryl Kato, Katie Ann Keaton, Sudha Kondappally, Chris Levins, Adam Littke, Ruben Martinez, Dominika Pcion, Troy Reynolds, Bruce Ross, Michael Sangi, Adam J. Schrier, Pamela Seng, Dustin Siegel, Nathan Shapiro, Donald Tang, James G. Taylor, Jonathan Tripp, Andrew W. Waltman, Lawrence Yu
  • Publication number: 20180179175
    Abstract: The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.
    Type: Application
    Filed: December 19, 2017
    Publication date: June 28, 2018
    Inventors: Kevin M. Allan, Shinji Fujimori, Lars V. Heumann, Grace May Huynh, Katie Ann Keaton, Christopher M. Levins, Ganapati Reddy Pamulapati, Benjamin James Roberts, Keshab Sarma, Martin Gerald Teresk, Xiang Wang, Scott Alan Wolckenhauer
  • Patent number: 9890134
    Abstract: The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: February 13, 2018
    Assignee: Gilead Pharmasset LLC
    Inventors: Kevin M. Allan, Shinji Fujimori, Lars V. Heumann, Grace May Huynh, Katie Ann Keaton, Chrisopher M. Levins, Ganapati Reddy Pamulapati, Benjamin James Roberts, Keshab Sarma, Martin Gerald Teresk, Xiang Wang, Scott Alan Wolckenhauer
  • Publication number: 20180022757
    Abstract: Methods of making compounds of Formula I are disclosed:
    Type: Application
    Filed: June 30, 2017
    Publication date: January 25, 2018
    Inventors: Anna Chiu, John Enquist, JR., Nolan Griggs, Christopher Hale, Norihiro Ikemoto, Katie Ann Keaton, Matt Kraft, Scott E. Lazerwith, Michel Leeman, Zhihui Peng, Kate Schrier, Jonathan Trinidad, Jochem Van Herpt, Andrew W. Waltman
  • Publication number: 20170333438
    Abstract: The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.
    Type: Application
    Filed: May 5, 2017
    Publication date: November 23, 2017
    Inventors: Ernest A. Carra, Irene Chen, Katie Ann Keaton, Scott E. Lazerwith, Vahid Zia
  • Publication number: 20170283390
    Abstract: The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.
    Type: Application
    Filed: April 28, 2017
    Publication date: October 5, 2017
    Inventors: Kevin M. Allan, Shinji Fujimori, Lars V. Heumann, Grace May Huynh, Katie Ann Keaton, Christopher M. Levins, Ganapati Reddy Pamulapati, Benjamin James Roberts, Keshab Sarma, Martin Gerald Teresk, Xiang Wang, Scott Alan Wolckenhauer
  • Publication number: 20170210756
    Abstract: The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.
    Type: Application
    Filed: August 3, 2016
    Publication date: July 27, 2017
    Inventors: Amy Cagulada, Johann Chan, Lina Chan, Denise A. Colby, Kapil Kumar Karki, Darryl Kato, Katie Ann Keaton, Sudha Kondapally, Christopher Levins, Adam Littke, Ruben Martinez, Dominika Pcion, Troy Reynolds, Bruce Ross, Michael Sangi, Adam J. Schrier, Pamela Seng, Dustin Siegel, Nathan Shapiro, Donald Tang, James G. Taylor, Jonathan Tripp, Andrew W. Waltman, Lawrence Yu
  • Patent number: 9682084
    Abstract: The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: June 20, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Ernest A. Carra, Irene Chen, Katie Ann Keaton, Scott E. Lazerwith, Vahid Zia
  • Patent number: 9670187
    Abstract: The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: June 6, 2017
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Kevin M. Allan, Shinji Fujimori, Lars V. Heumann, Grace May Huynh, Katie Ann Keaton, Christopher M. Levins, Ganapati Reddy Pamulapati, Benjamin James Roberts, Keshab Sarma, Martin Gerald Teresk, Xiang Wang, Scott Alan Wolckenhauer
  • Patent number: 9440991
    Abstract: The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: September 13, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Amy Cagulada, Johann Chan, Lina Chan, Denise A. Colby, Kapil Kumar Karki, Darryl Kato, Katie Ann Keaton, Sudha Kondapally, Chris Levins, Adam Littke, Ruben Martinez, Dominika Pcion, Troy Reynolds, Bruce Ross, Michael Sangi, Adam J. Schrier, Pamela Seng, Dustin Siegel, Nathan Shapiro, Donald Tang, James G. Taylor, Jonathan Tripp, Andrew W. Waltman, Lawrence Yu
  • Publication number: 20150366872
    Abstract: The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.
    Type: Application
    Filed: June 19, 2015
    Publication date: December 24, 2015
    Inventors: Ernest A. Carra, Irene Chen, Katie Ann Keaton, Vahid Zia
  • Publication number: 20150368264
    Abstract: Methods of making compounds of Formula I are disclosed:
    Type: Application
    Filed: June 16, 2015
    Publication date: December 24, 2015
    Inventors: Anna Chiu, John Enquist, JR., Nolan Griggs, Christopher Hale, Norihiro Ikemoto, Katie Ann Keaton, Matt Kraft, Scott E. Lazerwith, Michel Leeman, Zhihui Peng, Kate Schrier, Jonathan Trinidad, Jochem Van Herpt, Andrew W. Waltman
  • Publication number: 20150361073
    Abstract: The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.
    Type: Application
    Filed: June 8, 2015
    Publication date: December 17, 2015
    Inventors: Kevin M. Allan, Shinji Fujimori, Lars V. Heumann, Grace May Huynh, Katie Ann Keaton, Christopher M. Levins, Ganapati Reddy Pamulapati, Benjamin James Roberts, Keshab Sarma, Martin Gerald Teresk, Xiang Wang, Scott Alan Wolckenhauer
  • Publication number: 20150175626
    Abstract: The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.
    Type: Application
    Filed: December 18, 2014
    Publication date: June 25, 2015
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Amy Cagulada, Johann Chan, Lina Chan, Denise A. Colby, Kapil Kumar Karki, Darryl Kato, Katie Ann Keaton, Sudha Kondapally, Chris Levins, Adam Littke, Ruben Martinez, Dominika Pcion, Troy Reynolds, Bruce Ross, Michael Sangi, Adam J. Schrier, Pamela Seng, Dustin Siegel, Nathan Shapiro, Donald Tang, James G. Taylor, Jonathan Tripp, Andrew W. Waltman, Lawrence Yu